Company Overview of Eli Lilly Canada Inc.
Eli Lilly Canada Inc. develops pharmaceutical products. It offers medicines to treat pulmonary arterial hypertension, erectile dysfunction, depression, diabetes, osteoporosis, cancer and other life-threatening and life-changing illnesses. The company was founded in 1938 and is based in Toronto, Canada with a regional office in Guelph, Canada. Eli Lilly Canada Inc. operates as a subsidiary of Eli Lilly and Company.
3650 Danforth Avenue
Toronto, ON M1N 2E8
Founded in 1938
Key Executives for Eli Lilly Canada Inc.
President and General Manager
Director of Communications
Compensation as of Fiscal Year 2016.
Eli Lilly Canada Inc. Key Developments
Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Announce Health Canada Approves JARDIANCE as an Adjunct to Diet and Exercise
Nov 30 15
Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada announced that Health Canada has approved JARDIANCE to be used as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.1 JARDIANCE belongs to a new class of agents called sodium glucose co-transporter 2 (SGLT2) inhibitors that have a different mechanism of action from other oral glucose-lowering agents.2 JARDIANCE lowers the renal threshold for glucose, which leads to reduced renal reabsorption of filtered glucose and increased urinary glucose excretion.1.
Eli Lilly Canada Announces Introduction of Cyramza into Canada
Sep 21 15
Eli Lilly Canada announced that its new gastric cancer medicine, Cyramza, has been approved and is now available for use in Canada. Cyramza was authorized by Health Canada for use as a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with disease progression on or after prior platinum and fluoropyrimidine chemotherapy. In Canada, an estimated 3,400 new cases of gastric cancer are expected to be diagnosed in 2015, gastric cancer offers few discernible symptoms until the disease has reached an advanced stage 3,4. Consequently, patients are often diagnosed late in the progression of the disease, yielding poor outlooks for most patients. In Canada, the five year relative survival ratio is sixth-worst of all cancers, at approximately 25%. Cyramza is a human vascular endothelial growth factor receptor 2 antagonist and is administered as an IV solution by infusion. Clinical studies, including the RAINBOW and REGARD phase 3 trials, demonstrated Cyramza's efficacy and manageable side effect profile as a second-line therapy for gastric cancer 1,6,7.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries